KEY POINTS
- This prospective single-institution study included 27 patients treated between 2013 and 2015 with permanent breast seed implantation as accelerated partial breast irradiation. Eligibility was restrictive: age ≥50 years, tumor ≤3 cm, margins ≥2 mm, node-negative ductal invasive carcinoma or DCIS, no lymphovascular invasion, ECOG 0–1, and favorable anatomy for implantation.
- All patients received a single permanent palladium-103 implant prescribed to 90 Gy. Median tumor size was 0.8 cm, all patients were node-negative with negative margins, and none had HER2-positive disease. Median follow-up reached 10.0 years.
- Implant dosimetry was consistently high quality: median CTV V100 was 100%, PTV V90 97%, and PTV V100 94%. Median implant size was 64 seeds through 15 needles, with a median PTV volume of 47 cc.
- At 10 years there were no local recurrences, no distant recurrences, and no breast cancer-related deaths. Overall survival was 96.3% at 5 years and 88.3% at 10 years; all four deaths were unrelated to breast cancer.
- Acute skin reactions were documented in 7 of 27 patients (25.9%): one Grade 1 and five Grade 2 reactions, with one additional rash considered unrelated to radiation. No Grade ≥3 toxicity occurred.
- Cosmetic outcomes remained favorable. Excellent or good physician-rated cosmesis remained ≥90% throughout structured follow-up through 5 years; at year 5, among the 10 evaluable patients, 40% were rated excellent and 50% good.
- The technique relies heavily on procedural accuracy because permanent seeds cannot be optimized after implantation. The modified workflow used general anesthesia, a side-mounted stepper, triple verification of each needle deployment, and immediate day-0 CT dosimetry; however, the small sample, restrictive selection, single-center design, and declining cosmetic follow-up limit broader conclusions.
CLINICAL TAKEAWAY
Permanent breast seed implantation can provide durable control with a true single-session APBI workflow for carefully selected low-risk patients, potentially reducing treatment burden for those facing major travel or logistical barriers. The 10-year results are encouraging but should be viewed as supportive rather than comparative evidence because only 27 patients were treated and no control group was included.